

Flávia Sousa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/759668/publications.pdf>

Version: 2024-02-01

33
papers

1,269
citations

394286

19
h-index

477173

29
g-index

34
all docs

34
docs citations

34
times ranked

2134
citing authors

#	ARTICLE	IF	CITATIONS
1	Implantable and long-lasting drug delivery systems for cancer treatment. , 2022, , 129-162.		2
2	In vitro model for predicting the access and distribution of drugs in the brain using hCMEC/D3 cells. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 163, 120-126.	2.0	19
3	Intratumoral VEGF nanotrappner reduces glioblastoma vascularization and tumor cell mass. Journal of Controlled Release, 2021, 339, 381-390.	4.8	12
4	Structural and functional analysis of broad pH and thermal stable protease from <i>Penicillium aurantiogriseum</i> URM 4622. Preparative Biochemistry and Biotechnology, 2021, , 1-12.	1.0	0
5	Chitosan-based nanomedicine for brain delivery: Where are we heading?. Reactive and Functional Polymers, 2020, 146, 104430.	2.0	25
6	Effective intracellular delivery of bevacizumab <i>via</i> PEGylated polymeric nanoparticles targeting the CD44v6 receptor in colon cancer cells. Biomaterials Science, 2020, 8, 3720-3729.	2.6	24
7	Prediction of the enhanced insulin absorption across a triple co-cultured intestinal model using mucus penetrating PLGA nanoparticles. International Journal of Pharmaceutics, 2020, 585, 119516.	2.6	17
8	Engineering the drug carrier biointerface to overcome biological barriers to drug delivery. Advanced Drug Delivery Reviews, 2020, 167, 89-108.	6.6	91
9	The solid progress of nanomedicine. Drug Delivery and Translational Research, 2020, 10, 726-729.	3.0	91
10	In situ inflammatory-regulated drug-loaded hydrogels for promoting pelvic floor repair. Journal of Controlled Release, 2020, 322, 375-389.	4.8	42
11	Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles. Journal of Controlled Release, 2019, 309, 37-47.	4.8	74
12	Recent advance of erythrocyte-mimicking nanovehicles: From bench to bedside. Journal of Controlled Release, 2019, 314, 81-91.	4.8	22
13	Theranostic Biomaterials for Regulation of the Bloodâ€“Brain Barrier. , 2019, , 303-319.		4
14	Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology. Expert Opinion on Drug Delivery, 2019, 16, 271-285.	2.4	83
15	Alginate-Based Delivery Systems for Bevacizumab Local Therapy: InÂ“Vitro Structural Features and Release Properties. Journal of Pharmaceutical Sciences, 2019, 108, 1559-1568.	1.6	18
16	Incorporation of beads into oral films for buccal and oral delivery of bioactive molecules. Carbohydrate Polymers, 2018, 194, 411-421.	5.1	32
17	Development and characterization of lipid-polymeric nanoparticles for oral insulin delivery. Expert Opinion on Drug Delivery, 2018, 15, 213-222.	2.4	35
18	Polyester-Based Nanoparticles for the Encapsulation of Monoclonal Antibodies. Methods in Molecular Biology, 2018, 1674, 239-253.	0.4	13

#	ARTICLE	IF	CITATIONS
19	Polyester-Based Nanoparticles for Delivery of Therapeutic Proteins. <i>Methods in Molecular Biology</i> , 2018, 1674, 255-274.	0.4	4
20	Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications. <i>Advanced Healthcare Materials</i> , 2018, 7, 1701035.	3.9	173
21	Fab-conjugated PLGA nanoparticles effectively target cancer cells expressing human CD44v6. <i>Acta Biomaterialia</i> , 2018, 81, 208-218.	4.1	39
22	Biophysical, photochemical and biochemical characterization of a protease from <i>Aspergillus tamaritii</i> URM4634. <i>International Journal of Biological Macromolecules</i> , 2018, 118, 1655-1666.	3.6	5
23	Nanoparticles provide long-term stability of bevacizumab preserving its antiangiogenic activity. <i>Acta Biomaterialia</i> , 2018, 78, 285-295.	4.1	32
24	Therapeutic Monoclonal Antibodies Delivery for the Glioblastoma Treatment. <i>Advances in Protein Chemistry and Structural Biology</i> , 2018, 112, 61-80.	1.0	15
25	Carcinoembryonic antigen-targeted nanoparticles potentiate the delivery of anticancer drugs to colorectal cancer cells. <i>International Journal of Pharmaceutics</i> , 2018, 549, 397-403.	2.6	26
26	Biophysical study of bevacizumab structure and bioactivity under thermal and pH-stresses. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 105, 127-136.	1.9	23
27	Development and validation of a rapid reversed-phase HPLC method for the quantification of monoclonal antibody bevacizumab from polyester-based nanoparticles. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 142, 171-177.	1.4	20
28	A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles. <i>Scientific Reports</i> , 2017, 7, 3736.	1.6	92
29	Nanoparticles for the delivery of therapeutic antibodies: Dogma or promising strategy?. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 1163-1176.	2.4	59
30	Cell-based in vitro models for nasal permeability studies. , 2016, , 83-100.		7
31	How to overcome the limitations of current insulin administration with new non-invasive delivery systems. <i>Therapeutic Delivery</i> , 2015, 6, 83-94.	1.2	28
32	Oral films as breakthrough tools for oral delivery of proteins/peptides. <i>Journal of Controlled Release</i> , 2015, 211, 63-73.	4.8	51
33	Stability Study Perspective of the Effect of Freeze-Drying Using Cryoprotectants on the Structure of Insulin Loaded into PLGA Nanoparticles. <i>Biomacromolecules</i> , 2014, 15, 3753-3765.	2.6	89